AX-2026-043418 · BPC-157 · WXT lot WXT-2602-W3200

Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	97.79	% area	≥ 98.0	FAIL
Total impurities	RP-HPLC, sum of reported peaks	2.21	% area	≤ 2.0	FAIL
Largest single impurity	RP-HPLC — truncated (1-12)	1.01	% area	≤ 1.00	FAIL
Identity — theoretical monoisotopic mass	calculated from molecular formula	1418.7093	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	1418.7079	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-1.0	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	87.28	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	85.35	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	6.29	mg	5 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	5.369	mg	5 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	107.4	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	4.69	%	≤ 10.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	7.13	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.90	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	1.08	EU/mg	≤ 5.0	PASS
Sterility	membrane filtration, USP <71>, 14 d	No growth at 14 d	—	no growth	PASS
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear with a single visible fibre	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.26	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 25 min gradient	8.14	min	8.14 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.86	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	65,519	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Val]-diastereomer	0.89	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 65,519, and skew follows the reported asymmetry factor of 0.86. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 1.01 % impurity against a 97.79 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	BPC-157 — main peak	8.14	4,752,897	97.79	—
2	truncated (1-12)	7.34	49,089	1.01	-285.132
3	acetylated N-terminus (+42 Da)	8.54	31,592	0.65	+42.011
4	des-Gly truncate (−57 Da)	7.86	15,067	0.31	-57.021
5	[D-Val]-diastereomer	8.02	7,290	0.15	0.000
6	pyroglutamate cyclisation (−17 Da)	8.40	2,916	0.06	-17.027
7	BPC-157 arginine-salt artefact	7.68	1,458	0.03	0.000
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 1418.7093 Da, computed from C62H98N16O22. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 1418.7079 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
3+	473.9104	473.9099	-0.0005	9.0
2+	710.3619	710.3612	-0.0007	55.4
1+	1419.7166	1419.7152	-0.0014	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	4.69
Counter-ion (acetate)	ion chromatography	7.13
Residual solvent + inorganic residue	estimated	0.90
Total peptide content	by difference	87.28
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	97.76	97.79	divergence -0.08 pp vs batch median
Total impurities (% area)	2.24	2.21
Largest single impurity (% area)	1.17	1.01
Water (%)	3.1	4.69
Counter-ion (%)	not stated	7.13
Peptide content (%w/w)	not stated	87.28
Endotoxin (EU/mg)	not stated	1.08
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (2–8 °C, 21 d) → laboratory (courier, ambient, 5 d) → assay.
Assay date: 05 Jun 2026
Submitted to the index: 27 Jun 2026
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

wide_iqr27 Jun 2026

97.79 % on BPC-157 is below the index specification for the class. The interesting part is the distribution: truncated (1-12) at 1.01 % is doing most of the work, and that species is a synthesis artefact rather than a degradation product. This is a process observation about lot WXT-2602-W3200, not a storage one.

mass_defect27 Jun 2026

Before assigning truncated (1-12) from retention alone, check the mass defect on the impurity peak. Plausible and implausible assignments separate cleanly and the check costs nothing.

coa_reader27 Jun 2026

What would resolve this quickly is the batch record rather than the summary certificate — the in-process chromatogram, the fraction cut, and the reporting threshold applied. Every supplier scorecarded here holds one.

Section 7

Related records

Same batch — lot WXT-2602-W3200 n=7

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-043416	WXT-2602-W3200	Janoshik	2026-Q2	97.58	5.03	—	Buyer-sourced	FAIL
AX-2026-043417	WXT-2602-W3200	Janoshik	2026-Q2	97.84	5.24	—	Buyer-sourced	FAIL
AX-2026-043419	WXT-2602-W3200	Janoshik	2026-Q2	98.00	5.13	103.2	Supplier-supplied	PASS
AX-2026-043420	WXT-2602-W3200	Medutest	2026-Q2	98.03	4.96	107.4	Buyer-sourced	PASS
AX-2026-043421	WXT-2602-W3200	Medutest	2026-Q2	98.64	4.86	—	Supplier-supplied	PASS
AX-2026-043422	WXT-2602-W3200	Medutest	2026-Q2	97.45	4.49	93.4	Buyer-sourced	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent BPC-157 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043319	CPC	CPC-2602-W1610	Medutest	2026-Q3	98.82	2.88	103.5	Buyer-sourced	2	MARGINAL
AX-2026-041766	TFS	TFS-{CAT}-1156	Janoshik	2026-Q3	99.54	6.34	—	Buyer-sourced	1	MARGINAL
AX-2026-043445	BCH	BCH-2603-G4350	Nordanalyt	2026-Q3	98.42	4.87	93.6	Buyer-sourced	1	MARGINAL
AX-2026-043440	BCH	BCH-2603-G4350	VendorInvestigate	2026-Q3	98.61	4.11	—	Buyer-sourced	1	MARGINAL
AX-2026-043442	BCH	BCH-2603-G4350	Janoshik	2026-Q3	98.65	4.78	—	Buyer-sourced	1	MARGINAL
AX-2026-043449	BCH	BCH-2603-G4350	Kestrel	2026-Q3	99.74	4.92	91.3	Supplier-supplied	2	MARGINAL
AX-2026-043448	BCH	BCH-2603-G4350	Janoshik	2026-Q3	98.55	4.69	106.9	Buyer-sourced	1	MARGINAL
AX-2026-043318	CPC	CPC-2602-W1610	VendorInvestigate	2026-Q3	98.47	3.12	104.1	Buyer-sourced	1	MARGINAL

Other recent WXT records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043376	Semaglutide	WXT-2604-C3248	Janoshik	2026-Q3	97.08	4.22	—	Buyer-sourced	1	MARGINAL
AX-2026-043429	L-Glutathione (reduced)	WXT-2605-B3833	Nordanalyt	2026-Q3	98.48	6.58	96.9	Supplier-supplied	1	FAIL
AX-2026-043347	Leuprolide	WXT-2604-K2596	PeptideMeter	2026-Q3	99.16	5.99	93.6	Buyer-sourced	0	PASS
AX-2026-043353	Leuprolide	WXT-2604-K2596	Janoshik	2026-Q3	99.19	4.90	95.3	Laboratory-retained	0	PASS
AX-2026-043345	Leuprolide	WXT-2604-K2596	Janoshik	2026-Q3	98.93	5.28	—	Buyer-sourced	0	PASS
AX-2026-043424	L-Glutathione (reduced)	WXT-2605-B3833	PeptideMeter	2026-Q3	98.37	6.86	—	Buyer-sourced	0	FAIL
AX-2026-043374	Semaglutide	WXT-2604-C3248	Janoshik	2026-Q3	97.00	3.56	—	Buyer-sourced	1	MARGINAL
AX-2026-043377	Semaglutide	WXT-2604-C3248	PeptideMeter	2026-Q3	97.20	4.08	—	Buyer-sourced	1	MARGINAL